US2005192306A1PendingUtilityA1

Pyrimidine derivatives as selective inhibitors of COX-2

45
Priority: May 25, 2001Filed: May 2, 2005Published: Sep 1, 2005
Est. expiryMay 25, 2021(expired)· nominal 20-yr term from priority
Inventors:Jennifer Margaret DoughtyRichard Howard GreenCharles David HartleyAlan NaylorJeremy PayneNeil Anthony Pegg
A61P 35/00A61P 31/12A61P 3/10A61P 9/00A61P 31/16A61P 43/00A61P 25/02A61P 29/00A61P 25/08A61P 25/00A61P 25/04C07D 239/42A61P 17/02A61P 1/04A61P 17/00A61P 1/00A61P 21/00A61P 19/02A61P 17/06A61P 1/16A61P 19/06A61P 19/00
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating a subject suffering from a condition which is mediated by COX-2.

Claims

exact text as granted — not AI-modified
1 - 10 . (canceled)  
     
     
         11 . A method of treating a subject suffering from a condition which is mediated by COX-2 which comprises administering to said subject an effective amount of a compound of formula (I)  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, in which: 
 R 1  and R 2  are independently selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 alkynyl, C 3-10 cycloalkylC 0-6 alkyl and C 4-12 bridged cycloalkyl;  
 R 3  is selected from the group consisting of C 1-6 alkyl, NH 2  and R 5 CONH;  
 R 4  is selected from the group consisting of CH 2 F, CHF 2 , CF 3 CH 2 , CF 3 CHF and CF 3 CF 2 ; and  
 R 5  is selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylOC 1-6 alkyl, phenyl, HO 2 CC 1-6 alkyl, C 1-6 alkylOCOC 1-6 alkyl, C 1-6 alkylOCO, H 2 NC 1-6 alkyl, C 1-6 alkylOCONHC 1-6 alkyl and C 1-6 alkylCONHC 1-6 alkyl.  
 
     
     
         12 . A method of treating a subject suffering from an inflammatory disorder mediated by COX-2, which method comprises administering to said subject an effective amount of a compound of formula (I)  
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, in which:  
         R 1  and R 2  are independently selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 alkynyl, C 3-10 cycloalkylC 0-6 alkyl and C 4-12 bridged cycloalkyl;  
         R 3  is selected from the group consisting of C 1-6 alkyl, NH 2  and R 5 CONH;  
         R 4  is selected from the group consisting of CH 2 F, CHF 2 , CF 3 CH 2 , CF 3 CHF and CF 3 CF 2 ; and  
         R 5  is selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylOC 1-6 alkyl, phenyl, HO 2 CC 1-6 alkyl, C 1-6 alkylOCOC 1-6 alkyl, C 1-6 alkylOCO, H 2 NC 1-6 alkyl, C 1-6 alkylOCONHC 1-6 alkyl and C 1-6 alkylCONHC 1-6 alkyl.  
       
     
     
         15 . The method according to  claim 11 , wherein said subject is a human.  
     
     
         16 . The method according to  claim 12 , wherein said subject is a human.

Join the waitlist — get patent alerts

Track US2005192306A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.